LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

30.83 3.32

Overview

Share price change

24h

Current

Min

29.05

Max

31.4

Key metrics

By Trading Economics

Income

-16M

-97M

Sales

361K

361K

EPS

-1.04

Profit margin

-26,807.202

Employees

437

EBITDA

-17M

-110M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+145.36% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-185M

3B

Previous open

27.51

Previous close

30.83

News Sentiment

By Acuity

50%

50%

168 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Jun 2025, 23:49 UTC

Acquisitions, Mergers, Takeovers

Xero to Buy Melio for Initial US$2.5 Billion in U.S. Growth Play -- Update

24 Jun 2025, 23:39 UTC

Hot Stocks

Stocks to Watch: Torrid Holdings, FedEx, QuantumScape

24 Jun 2025, 22:58 UTC

Earnings

FedEx Shares Mixed Outlook as Tariffs Roil International Customers -- 2nd Update

24 Jun 2025, 22:37 UTC

Acquisitions, Mergers, Takeovers

Xero Acquires Melio for Initial US$2.5 Billion in U.S. Growth Play

24 Jun 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 Jun 2025, 23:45 UTC

Market Talk

Nikkei May Trade Rangebound Amid Middle East Uncertainty -- Market Talk

24 Jun 2025, 23:40 UTC

Market Talk

Gold Steady Amid Fed Rate-Cut Prospects -- Market Talk

24 Jun 2025, 23:18 UTC

Market Talk

Briscoe Rallies Too Hard for Forsyth Barr -- Market Talk

24 Jun 2025, 23:07 UTC

Market Talk

Australian Inflation Data Set to Green Light RBA Cut -- Market Talk

24 Jun 2025, 23:06 UTC

Market Talk

Reliance Worldwide's U.S. Headwinds to Remain into FY26 -- Market Talk

24 Jun 2025, 23:05 UTC

Earnings

FedEx Posts Growth, Mixed Outlook Amid Tariffs and Inflation -- 2nd Update

24 Jun 2025, 23:04 UTC

Market Talk

Global Equities Roundup: Market Talk

24 Jun 2025, 23:04 UTC

Market Talk

FedEx to Feel Pressure From De Minimis Exemption Ending -- Market Talk

24 Jun 2025, 22:57 UTC

Market Talk

Australia's Chalmers in Critical Talks With Bessent -- Market Talk

24 Jun 2025, 22:55 UTC

Market Talk

Unpredictable Trade Policy Keeps FedEx Outlook Narrow -- Market Talk

24 Jun 2025, 22:55 UTC

Acquisitions, Mergers, Takeovers

Krafton Is a South Korean Videogame Developer

24 Jun 2025, 22:55 UTC

Acquisitions, Mergers, Takeovers

Woodside CEO Says Strong Interest Remains From Potential Partners in Louisiana LNG

24 Jun 2025, 22:54 UTC

Acquisitions, Mergers, Takeovers

Krafton: Acquisition Aims to Diversify Business in Japan

24 Jun 2025, 22:54 UTC

Acquisitions, Mergers, Takeovers

Krafton: K.K. BCJ-31 Is Parent of Advertising-Animation Group ADK Holdings

24 Jun 2025, 22:54 UTC

Acquisitions, Mergers, Takeovers

Krafton Acquires Japan's K.K. BCJ-31 for KRW710.37B

24 Jun 2025, 22:54 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy Completes Sale of 40% Stake in Louisiana LNG Infrastructure to Stonepeak

24 Jun 2025, 22:14 UTC

Acquisitions, Mergers, Takeovers

Xero: Acquisition of Bill-Pay Provider Meets Critical U.S. Customer Need

24 Jun 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

Xero Sees Opportunity to More Than Double Revenue by FY28

24 Jun 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

Xero Expects Combined Business to Significantly Accelerate U.S. Revenue Growth

24 Jun 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

Xero Expects to Keep Generating Positive Cash-Flow Following Transaction

24 Jun 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

Xero To Acquire Melio, A Leading US SMB Bill Pay Solution, To Accelerate Global Growth >XRO.AU

24 Jun 2025, 22:09 UTC

Acquisitions, Mergers, Takeovers

Xero: Up-Front Consideration Values Melio at 13.4 Times Annualized Revenue

24 Jun 2025, 22:08 UTC

Acquisitions, Mergers, Takeovers

Xero to Use US$600 Mln of Existing Cash on Balance Sheet

24 Jun 2025, 22:08 UTC

Acquisitions, Mergers, Takeovers

Xero to Use US$400 Mln Unsecured Revolving Credit Facility

24 Jun 2025, 22:08 UTC

Acquisitions, Mergers, Takeovers

Xero to Give US$360 Mln in Stock to Melio Shareholders

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

145.36% upside

12 Months Forecast

Average 74 USD  145.36%

High 97 USD

Low 53 USD

Based on 8 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

30.39 / 33.46Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

168 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.